PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Semin Liver Dis 2023; 43(03): 336-350
DOI: 10.1055/a-2153-8836
Review Article

Research Progress on the Role and Mechanism of IL-37 in Liver Diseases

Baoyi Jiang
1   Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China
,
Yulin Zhou
2   Department of Clinical Laboratory, Shunde New Rongqi Hospital, Foshan, China
,
Yanting Liu
1   Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China
,
Siqi He
1   Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China
,
Baojian Liao
1   Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China
,
Tieli Peng
1   Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China
,
Leyi Yao
1   Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China
,
Ling Qi
1   Institute of Digestive Disease, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan, China
› Institutsangaben
Funding The study is supported in part by grant no. 20211458 from the Foundation of Traditional Chinese Medicine Bureau of Guangdong Province; no. 2022108 from the Foundation of Student Innovation Ability Promotion Plan of Guangzhou Medical University; no. 20190220 from the Foundation of Qingyuan People's Hospital (Qingyuan, Guangdong; to Prof. Ling Qi).
› Weitere Informationen
  Lizenzen und Reprints


Preview

Abstract

Cytokines are important components of the immune system that can predict or influence the development of liver diseases. IL-37, a new member of the IL-1 cytokine family, exerts potent anti-inflammatory and immunosuppressive effects inside and outside cells. IL-37 expression differs before and after liver lesions, suggesting that it is associated with liver disease; however, its mechanism of action remains unclear. This article mainly reviews the biological characteristics of IL-37, which inhibits hepatitis, liver injury, and liver fibrosis by inhibiting inflammation, and inhibits the development of hepatocellular carcinoma (HCC) by regulating the immune microenvironment. Based on additional evidence, combining IL-37 with liver disease markers for diagnosis and treatment can achieve more significant effects, suggesting that IL-37 can be developed into a powerful tool for the clinical adjuvant treatment of liver diseases, especially HCC.

Keywords

IL-37 - hepatitis - liver injury - liver fibrosis - HCC

Authors' Contribution

B.J. and Y.Z. contributed to manuscript writing; Y.L., B.L., and T.P. conducted literature retrieval; and L.Y. and L.Q. revised the manuscript.




Publikationsverlauf

Accepted Manuscript online:
15. August 2023

Artikel online veröffentlicht:
11. September 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA